UCB is bringing drug manufacturing to the United States for the first time, with plans to invest $2 billion in a new facility in Georgia.
The company said the site will be built in Gwinnett County and will focus on producing biologic medicines. It marks a major shift for UCB, which has relied on outside partners for manufacturing. By building its own facility in the U.S., the company will have better control over how its products are made and delivered.
“This decision reflects our confidence in UCB’s long-term growth,” said Jean-Christophe Tellier in the official announcement…